

Our Ref: 61/2022  
JANUARY 2022

**Re: Your request made under the Freedom of Information Act 2000**

Wilmington Healthcare is looking to understand the usage of Biologic drugs in Gastroenterology. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for any medical condition, and if possible, for Ulcerative Colitis, with the following biologic drugs:

Treatments	Total Gastroenterology Patients	Ulcerative Colitis Patients
Adalimumab - Humira	15	10
Adalimumab Biosimilar	107	47
Filgotinib	0	0
Golimumab	3	3
Infliximab - Remicade	0	0
Infliximab Biosimilar	172	73
Ozanimod	0	0
Tofacitinib	1	1
Ustekinumab	33	8
Vedolizumab	88	43